腹膜超滤衰竭的机制及干预的研究进展.pdfVIP

·742 · 中华临床医师杂志( 电子版)2014 年3 月第8 卷第4 期 Chin J Clinicians(Electronic Edition),February 15,2014,Vol.8,No.4 ·综述· 腹膜超滤衰竭的机制及干预的研究进展 陈少霞 龚莉 【摘要】 随着慢性肾脏病发病率的不断增加，接受腹膜透析治疗的患者人数逐年上升，但超滤 衰竭是长期腹膜透析患者选择终止治疗的主要的原因之一。为了对临床开展延缓超滤衰竭的研究提 供新的理论依据，本文综述了腹膜超滤衰竭机制的影响因素及干预研究，认为低葡萄糖降解产物腹 膜透析液、微小RNA 、水通道蛋白激动剂、转化生长因子-β 抑制物、抗氧化剂、肾素-血管紧张素- 醛固酮系统（RAAS ）抑制剂、雷帕霉素、己酮可可碱、舒拉明、沙利度胺、塞来昔布、苯磷硫胺 等均可延缓腹膜超滤衰竭，可为临床干预超滤衰竭的研究提供新的方向。 【关键词】 腹膜透析； 肾功能衰竭； 干预 Advance in research of the mechanism and prevention of peritoneal ultrafiltration failure Chen * * Shaoxia , Gong Li. Graduate School of Inner Mongolia Medical University, Hohhot 010017, China Corresponding author: Gong Li, Email: gongl163.com 【Abstract 】 With the increasing of the number of patients with end-stage renal disease, the number of patients with peritoneal dialysis is rising. However, ultrafiltration failure is one of the main reasons to terminate the treatment of patients on long-term peritoneal dialysis. To provide new therapies for ultrafiltration failure, this article reviews the currently available data on impacts and prevention of peritoneal ultrafiltration failure and these studies can provide new directions to alleviate ultrafiltration failure in clinic, such as low glucose degradation products peritoneal dialysis solution, small RNA, pharmacological agonists of aquaporins, TGF-β inhibitors, mesothelial transplantation, antioxidants, renin-angiotensin-aldosterone system inhibitors, rapamycin, pentoxifylline, suramin, thalidomide, celecoxib and benfotiamine. 【Key words 】 Peritoneal dialysis; Kidney failure; Prevention 腹膜透析是终末期肾脏病的主要替代治疗之 的增厚、新生血管形成、上皮-间充质转化（epithelial 一，随着慢性肾脏病发病率的不断增加，接受腹膜 to mesenchymal transition ，EMT ）等。功能方面表 透析治疗的患者人数逐年